List of Excipients in Branded Drug AMBISOME

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Astellas Pharma US Inc	AMBISOME	amphotericin b	0469-3051	.ALPHA.-TOCOPHEROL
Astellas Pharma US Inc	AMBISOME	amphotericin b	0469-3051	CHOLESTEROL
Astellas Pharma US Inc	AMBISOME	amphotericin b	0469-3051	DISTEAROYLPHOSPHATIDYLGLYCEROL, DL-
Astellas Pharma US Inc	AMBISOME	amphotericin b	0469-3051	HYDROGENATED SOYBEAN LECITHIN
Astellas Pharma US Inc	AMBISOME	amphotericin b	0469-3051	SODIUM SUCCINATE HEXAHYDRATE
Astellas Pharma US Inc	AMBISOME	amphotericin b	0469-3051	SUCROSE
Astellas Pharma US Inc	AMBISOME	amphotericin b	0469-3051	WATER

AMBISOME Excipient Strategy and Commercial Opportunities

Last updated: September 24, 2026

AmBisome is a liposomal formulation of amphotericin B in which excipients determine drug loading, particle stability, tissue distribution, renal tolerability, lyophilized shelf life, and manufacturing complexity. The core opportunity is not a new active ingredient. It is control of the liposome platform, excipient quality, sterile manufacturing, analytical comparability, and differentiated delivery.

AmBisome contains amphotericin B, hydrogenated soy phosphatidylcholine, distearoylphosphatidylglycerol, cholesterol, alpha-tocopherol, and sucrose. The product is supplied as a 50 mg lyophilized vial for intravenous infusion and is reconstituted with sterile water before dilution in dextrose solution.[1]

What excipients are used in AmBisome?

The AmBisome formulation uses a defined phospholipid-cholesterol liposome system with sucrose as the principal lyoprotectant.

Component	Approximate amount per 50 mg vial	Primary function
Amphotericin B	50 mg	Antifungal active ingredient
Hydrogenated soy phosphatidylcholine, HSPC	213 mg	Structural bilayer phospholipid
Distearoylphosphatidylglycerol, DSPG	84 mg	Anionic phospholipid; improves drug association and particle charge
Cholesterol	52 mg	Membrane rigidity and permeability control
Alpha-tocopherol	0.64 mg	Oxidation control
Sucrose	900 mg	Cryoprotectant and lyoprotectant
Sterile water for injection	Added during reconstitution	Reconstitution vehicle
Dextrose solution	Used for final dilution	Infusion vehicle

The formulation does not rely on conventional surfactants or a large aqueous solubilizer system. Amphotericin B is associated with the lipid bilayer, reducing exposure to free drug compared with conventional amphotericin B deoxycholate.[1,2]

Why HSPC matters commercially

HSPC is a high-transition-temperature phospholipid. Its saturated fatty-acid profile supports a relatively rigid bilayer and contributes to liposome integrity during storage and infusion. Pharmaceutical-grade HSPC supply is concentrated among specialist lipid manufacturers, creating qualification, pricing, and continuity risks.

A supplier seeking commercial entry can compete through:

• Pharmaceutical-grade HSPC with tight purity specifications.
• Low peroxide and low lysophospholipid levels.
• Consistent fatty-acid distribution.
• Sterile or low-bioburden material.
• Multi-site manufacturing and contingency inventory.
• Regulatory documentation supporting global filings.

Why DSPG matters commercially

DSPG provides a negatively charged lipid component. Its charge influences amphotericin B association, particle size, aggregation behavior, biodistribution, and interaction with plasma proteins.

DSPG is less interchangeable than a conventional neutral phospholipid. A substitution with another anionic phospholipid could change:

• Encapsulation or association efficiency.
• Free amphotericin B levels.
• Particle-size distribution.
• Release kinetics.
• Infusion tolerability.
• Tissue distribution.
• Immunogenicity and complement activation.

A new DSPG supplier would therefore need to demonstrate more than chemical identity. Lot-to-lot control of acyl-chain composition, oxidation, hydrolysis, residual solvents, and trace metals would be commercially important.

How does each excipient contribute to AmBisome performance?

AmBisome is a multi-excipient system. The commercial value of the formulation comes from the interaction between the components rather than from any single excipient.

Cholesterol

Cholesterol reduces membrane permeability and strengthens the liposomal bilayer. Its ratio to phospholipid affects amphotericin B retention and the physical stability of the particle.

Potential development risks include:

• Polymorphic or crystalline variation.
• Oxidative degradation.
• Residual solvent burden.
• Variability in particle structure.
• Changes in drug release after scale-up.

Cholesterol is widely available, so it is less likely to be the principal supply bottleneck. The critical issue is pharmaceutical quality and control within the finished liposome.

Alpha-tocopherol

Alpha-tocopherol functions as an antioxidant. Lipid oxidation can alter membrane integrity and generate degradation products that affect stability, safety, or release.

Commercial opportunities include pharmaceutical-grade alpha-tocopherol with:

• Low peroxide value.
• Controlled residual solvents.
• Defined stereochemical composition.
• Stable supply under controlled storage.
• Validated compatibility with phospholipids.

The low concentration does not eliminate its importance. Trace antioxidants can materially affect long-term stability in a lipid formulation.

Sucrose

Sucrose protects the liposome during freezing and drying. It helps preserve the bilayer during lyophilization and supports reconstitution.

The key variables are:

• Residual moisture.
• Collapse temperature.
• Cake structure.
• Reconstitution time.
• Particle-size recovery after reconstitution.
• Amphotericin B aggregation.
• Container-closure performance.

Sucrose is a commodity excipient, but pharmaceutical-grade quality and lyophilization performance remain relevant. A change in sucrose grade, particle size, moisture, or impurity profile can require comparability work.

What formulation attributes must a competing AmBisome product match?

A generic or 505(b)(2) developer must treat AmBisome as a complex drug product rather than as a simple amphotericin B injection.

Important quality attributes include:

Attribute	Commercial and regulatory relevance
Mean particle size	Controls distribution, stability, and comparability
Polydispersity	Indicates batch uniformity and aggregation risk
Zeta potential	Reflects surface charge and colloidal behavior
Free amphotericin B	Directly affects tolerability and pharmacology
Total drug concentration	Supports dose accuracy
Drug-to-lipid ratio	Central to formulation identity
Lipid composition	Affects bilayer structure and release
Encapsulation or association state	Defines product behavior
Reconstitution time	Affects hospital usability
Infusion compatibility	Controls administration risk
Residual moisture	Drives shelf life and physical stability
Oxidative degradation	Affects lipid and drug quality
Sterility and endotoxin	Required for intravenous administration

The most defensible commercial strategy is to establish a strong analytical similarity package before clinical development. Conventional assays for amphotericin B content are not enough. Developers need orthogonal methods for particle structure, free drug, lipid composition, morphology, thermal behavior, and release.

What FDA regulatory pathway applies to an AmBisome competitor?

AmBisome is an approved liposomal drug product under FDA NDA 050740. The main U.S. entry routes are an abbreviated new drug application or, depending on the proposed differences, a 505(b)(2) application.[1,3]

ANDA pathway

An ANDA applicant would need to demonstrate pharmaceutical equivalence and bioequivalence to the reference listed drug. Liposomal products can require extensive product-specific evidence because conventional systemic pharmacokinetic endpoints may not fully characterize equivalence.

Potential FDA expectations may include:

• Comparative physicochemical characterization.
• Comparative in vitro release.
• Comparative lipid and drug composition.
• Comparative particle-size distribution.
• Comparative free-drug fraction.
• Pharmacokinetic studies.
• Immunogenicity or safety assessment where relevant.
• Manufacturing-process controls.

505(b)(2) pathway

A 505(b)(2) application may be more suitable where the developer changes:

• Lipid composition.
• Concentration.
• Dosage form.
• Reconstitution system.
• Infusion presentation.
• Administration route.
• Indication.
• Delivery profile.

The tradeoff is a broader development package and potentially greater clinical or regulatory risk.

What is the Orange Book and exclusivity status of AmBisome?

AmBisome is an old approved product, and its original new chemical entity exclusivity period has expired. Current commercial barriers are therefore more likely to arise from complex formulation development, manufacturing know-how, regulatory requirements, supply control, and any active formulation or process patents than from NCE exclusivity.[1,3]

The relevant U.S. reference product is AmBisome, NDA 050740, held commercially by Gilead Sciences. FDA Orange Book records should be reviewed for current patent listings, pediatric exclusivity, and any changes affecting an ANDA filing strategy.[3]

What patents protect AmBisome?

The historical patent estate for liposomal amphotericin B has included claims directed to:

• Liposomal composition.
• Amphotericin B-to-lipid ratios.
• Phospholipid combinations.
• Particle characteristics.
• Lyophilized formulations.
• Methods of treating fungal infections.
• Manufacturing and reconstitution methods.

The practical position is that early platform patents may be expired or close to expiration, while later patents can still create targeted risks if they claim specific formulations, processes, or methods of use. Patent scope must be assessed claim by claim in the United States and each target market.

When does AmBisome lose exclusivity?

AmBisome has already lost its original NCE exclusivity. The timing of generic entry depends on:

1. FDA approval of an ANDA or 505(b)(2) application.
2. Any current Orange Book-listed patents.
3. Paragraph IV certifications.
4. Thirty-month stays or other litigation effects.
5. Regulatory exclusivities attached to a specific indication or supplement.
6. The applicant's ability to demonstrate equivalence for the complex liposome.

What paragraph IV challenges and generic entry risks exist?

A paragraph IV challenge is relevant only when an applicant certifies that a listed patent is invalid, unenforceable, or will not be infringed. The commercial value of such a challenge depends on the remaining patent term and the likelihood that the reference-product sponsor will obtain a litigation stay.

For AmBisome, the principal generic entry risk is technical rather than purely legal. A developer may face failure at several points:

• Inability to reproduce the reference particle population.
• Excess free amphotericin B.
• Inadequate reconstitution performance.
• Uncontrolled lipid oxidation.
• Batch variability during scale-up.
• Insufficient evidence of bioequivalence.
• Difficulty demonstrating comparable clinical tolerability.

A first approved generic could obtain a substantial advantage if it achieves reliable manufacturing and secures early hospital formulary adoption. Price erosion may be slower than for conventional injectables because liposomal products have fewer qualified manufacturers and higher validation costs.

Is AmBisome exposed to biosimilar competition?

No. AmBisome is not a biologic and is not regulated through the biosimilar pathway. It is a complex liposomal small-molecule drug product.

Its competitive risk comes from:

• Generic liposomal amphotericin B.
• 505(b)(2) reformulations.
• Conventional amphotericin B deoxycholate in cost-sensitive settings.
• Other systemic antifungal agents.
• Regional products for visceral leishmaniasis and invasive fungal disease.

What commercial opportunities exist in AmBisome excipients?

Excipient supply

The most direct opportunity is supplying pharmaceutical-grade lipid excipients. Attractive targets include HSPC and DSPG because they are more formulation-specific than sucrose or cholesterol.

A competitive supplier should offer:

• GMP production.
• Full traceability of animal and plant-derived materials.
• Tight oxidation and hydrolysis controls.
• Change-control commitments.
• Regulatory support packages.
• Dual-site supply.
• Small-scale development quantities and commercial-scale capacity.

Contract development and manufacturing

CDMOs can create value through:

• Liposome process development.
• High-shear or controlled-mixing scale-up.
• Aseptic filling.
• Lyophilization cycle development.
• Container-closure qualification.
• Release testing for complex liposomes.
• Comparability studies for generic applicants.

The highest-margin services are likely to be analytical and process-development activities, because sponsors often lack internal methods for free-drug measurement, particle characterization, and lipid degradation profiling.

Differentiated presentations

Potential product opportunities include:

• Ready-to-use infusion formats.
• Reduced reconstitution time.
• Smaller vial presentations.
• Improved cold-chain tolerance.
• Lower-cost regional presentations.
• Pediatric dosing formats.
• Extended-stability products.
• Hospital pharmacy systems that reduce preparation steps.

Each change can trigger a new regulatory and patent analysis. A simpler presentation may have greater commercial value than a new lipid composition if it reduces medication-preparation errors and pharmacy labor.

Geographic opportunities

AmBisome demand is strongest where invasive fungal infections, HIV-associated cryptococcal disease, visceral leishmaniasis, and severe immunosuppression create demand for safer amphotericin therapy.

Relevant commercial regions include:

• United States and Canada.
• European Union and United Kingdom.
• Latin America.
• India.
• Southeast Asia.
• Sub-Saharan Africa.

Price-sensitive markets may favor local fill-finish, regional lipid sourcing, or public-sector procurement agreements. The manufacturing strategy must preserve particle quality while reducing freight, cold-chain, and sterile-processing costs.

How strong is the AmBisome patent estate?

The patent estate is likely strongest around formulation implementation and manufacturing control rather than the amphotericin B molecule itself. A commercial assessment should score each patent family against five factors:

Factor	Strategic question
Claim breadth	Does the claim cover the full lipid system or a narrow ratio?
Remaining term	Does the term extend beyond the expected filing and launch date?
Validity	Are the claims vulnerable to prior-art or enablement challenges?
Detectability	Can infringement be established from the finished product or public process?
Design-around potential	Can a competitor alter composition or process without losing performance?

Process patents can create a meaningful barrier when manufacturing conditions are difficult to detect or replicate. Composition claims are more valuable when they cover a narrow range that is necessary for comparable performance.

What litigation, licensing, and settlement issues affect AmBisome?

The originator history is linked to NeXstar Pharmaceuticals, which was acquired by Gilead Sciences. Gilead commercialized AmBisome and remains the principal reference-product sponsor.[4]

Commercial diligence should focus on:

• Current ownership of formulation and process patents.
• Any licenses granted by earlier liposome technology owners.
• Patent assignments following corporate acquisitions.
• ANDA paragraph IV notices.
• Litigation stays.
• Settlement agreements affecting launch dates.
• Authorized-generic arrangements.
• Regional licensing and distribution rights.

A settlement can delay generic launch without preserving a broad patent monopoly. Its economic effect depends on the agreed entry date, permitted indications, supply rights, and restrictions on authorized competition.

Key Takeaways

• AmBisome's commercial performance depends on HSPC, DSPG, cholesterol, alpha-tocopherol, and sucrose acting as an integrated liposome system.
• HSPC and DSPG offer the strongest excipient-supply opportunities because they are formulation-specific and quality-sensitive.
• The principal generic barrier is complex-product equivalence, not NCE exclusivity.
• AmBisome is exposed to generic and 505(b)(2) competition, not biosimilar competition.
• Analytical comparability, free-drug control, particle-size control, and lyophilization are central to market entry.
• CDMO, lipid supply, sterile fill-finish, analytical testing, and differentiated presentation opportunities are commercially stronger than simple commodity excipient supply.
• Patent diligence should focus on active formulation, process, method-of-use, and Orange Book-listed rights rather than the expired amphotericin B molecule.
• Regional opportunities are strongest where antifungal demand is high and hospital systems value reduced nephrotoxicity and reliable intravenous administration.

FAQs

Can HSPC be replaced in an AmBisome generic?

Yes, but replacement creates a comparability burden. A substitute phospholipid can change particle size, drug association, release, oxidation, and tolerability. Maintaining HSPC is generally the lower-risk strategy for an ANDA-oriented product.

Is DSPG a critical quality attribute or only an excipient?

DSPG is an excipient and a critical formulation component. Its charge and acyl-chain profile affect liposome structure and amphotericin B behavior, making it relevant to product performance and regulatory comparability.

Can a company commercialize liposomal amphotericin B without using AmBisome's exact excipient ratios?

Potentially, through a distinct formulation and an appropriate regulatory pathway. A changed formulation may require a 505(b)(2) application, additional clinical evidence, and a separate patent analysis.

What is the largest manufacturing barrier for an AmBisome competitor?

The largest barrier is consistent large-scale production of a sterile, lyophilized liposome with controlled particle size, low free amphotericin B, stable lipid composition, acceptable reconstitution, and validated shelf life.

Are excipient suppliers exposed to patent infringement risk?

Usually less directly than finished-product sponsors, but risk can arise when a supplier knowingly enables a patented formulation or provides a material with specifications designed to practice a claimed process. Supply agreements should address field of use, indemnity, and regulatory-change obligations.

References

1. U.S. Food and Drug Administration. (2023). AmBisome (amphotericin B) liposome for injection: Prescribing information. Gilead Sciences, Inc.

2. Adler-Moore, J. P., & Proffitt, R. T. (2002). AmBisome: Liposomal formulation, structure, mechanism of action and pre-clinical experience. Journal of Antimicrobial Chemotherapy, 49(Suppl. 1), 21-30.

3. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

4. Gilead Sciences, Inc. (n.d.). AmBisome product and company information. https://www.gilead.com/encore/ambisome